| Cell line name |
SKOV3-CisR |
|---|
| Accession |
CVCL_UI88 |
|---|
| Resource Identification Initiative |
To cite this cell line use: SKOV3-CisR (RRID:CVCL_UI88) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795. |
|---|
| Sequence variations |
- Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Ovarian serous cystadenocarcinoma (NCIt: C7978) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0532 (SK-OV-3) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
64Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=21372221; DOI=10.1158/1078-0432.CCR-10-2289
Santiskulvong C., Konecny G.E., Fekete M., Chen K.-Y.M., Karam A., Mulholland D., Eng C., Wu H., Song M., Dorigo O.
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Clin. Cancer Res. 17:2373-2384(2011) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_UI88
|
|---|
| Encyclopedic resources |
Wikidata; Q98132684
|
|---|
| Entry history |
|---|
| Entry creation | 25-Feb-2019 |
|---|
| Last entry update | 05-Oct-2023 |
|---|
| Version number | 8 |
|---|